Cargando…

Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis

The aim of this study was to identify possible failure-specific prognostic factors in non-small-cell lung cancer. Clinical outcome was analysed in 549 patients participating in the randomized controlled trial of CHART vs conventional radiotherapy. Local failure and distant failure with or without co...

Descripción completa

Detalles Bibliográficos
Autores principales: Ataman, Ö U, Bentzen, S M, Saunders, M I, Dische, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375163/
https://www.ncbi.nlm.nih.gov/pubmed/11710822
http://dx.doi.org/10.1054/bjoc.2001.2049
_version_ 1782154591735906304
author Ataman, Ö U
Bentzen, S M
Saunders, M I
Dische, S
author_facet Ataman, Ö U
Bentzen, S M
Saunders, M I
Dische, S
author_sort Ataman, Ö U
collection PubMed
description The aim of this study was to identify possible failure-specific prognostic factors in non-small-cell lung cancer. Clinical outcome was analysed in 549 patients participating in the randomized controlled trial of CHART vs conventional radiotherapy. Local failure and distant failure with or without concurrent local relapse were subjected to a competing risk analysis using an accelerated failure-time model with a log-logistic hazard function. Randomization to CHART (2 P = 0.005), increasing age (2 P = 0.036) and female sex (2 P = 0.09) was all associated with a prolonged interval to failure. Advanced clinical stage was associated with a decreased interval to failure (2 P = 0.004) and a significantly increased risk (2 P = 0.009) of failing in distant rather than in local position. From this model, prognostic indices for local and distant failure were estimated for each individual patient. Competing risk analysis allows identification of patients with different failure patterns, and may provide a means of stratifying patients for intensified local or systemic therapy. © 2001 Cancer Research Campaign  http://www.bjcancer.com
format Text
id pubmed-2375163
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23751632009-09-10 Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis Ataman, Ö U Bentzen, S M Saunders, M I Dische, S Br J Cancer Regular Article The aim of this study was to identify possible failure-specific prognostic factors in non-small-cell lung cancer. Clinical outcome was analysed in 549 patients participating in the randomized controlled trial of CHART vs conventional radiotherapy. Local failure and distant failure with or without concurrent local relapse were subjected to a competing risk analysis using an accelerated failure-time model with a log-logistic hazard function. Randomization to CHART (2 P = 0.005), increasing age (2 P = 0.036) and female sex (2 P = 0.09) was all associated with a prolonged interval to failure. Advanced clinical stage was associated with a decreased interval to failure (2 P = 0.004) and a significantly increased risk (2 P = 0.009) of failing in distant rather than in local position. From this model, prognostic indices for local and distant failure were estimated for each individual patient. Competing risk analysis allows identification of patients with different failure patterns, and may provide a means of stratifying patients for intensified local or systemic therapy. © 2001 Cancer Research Campaign  http://www.bjcancer.com Nature Publishing Group 2001-10 /pmc/articles/PMC2375163/ /pubmed/11710822 http://dx.doi.org/10.1054/bjoc.2001.2049 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Ataman, Ö U
Bentzen, S M
Saunders, M I
Dische, S
Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis
title Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis
title_full Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis
title_fullStr Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis
title_full_unstemmed Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis
title_short Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis
title_sort failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (chart) or conventional radiotherapy in locally advanced non-small-cell lung cancer: a competing risks analysis
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375163/
https://www.ncbi.nlm.nih.gov/pubmed/11710822
http://dx.doi.org/10.1054/bjoc.2001.2049
work_keys_str_mv AT atamanou failurespecificprognosticfactorsaftercontinuoushyperfractionatedacceleratedradiotherapychartorconventionalradiotherapyinlocallyadvancednonsmallcelllungcanceracompetingrisksanalysis
AT bentzensm failurespecificprognosticfactorsaftercontinuoushyperfractionatedacceleratedradiotherapychartorconventionalradiotherapyinlocallyadvancednonsmallcelllungcanceracompetingrisksanalysis
AT saundersmi failurespecificprognosticfactorsaftercontinuoushyperfractionatedacceleratedradiotherapychartorconventionalradiotherapyinlocallyadvancednonsmallcelllungcanceracompetingrisksanalysis
AT disches failurespecificprognosticfactorsaftercontinuoushyperfractionatedacceleratedradiotherapychartorconventionalradiotherapyinlocallyadvancednonsmallcelllungcanceracompetingrisksanalysis